Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female adults aged ≥ 40 years with a diagnosis of COPD~* Current smokers or ex-smokers~* A post-bronchodilator FEV1 \< 50% of the predicted normal value and a post- bronchodilator FEV1/FVC \< 0.7~* At least one exacerbation in the 12 months preceding the screening visit~Exclusion Criteria:~* Pregnant or lactating women~* Diagnosis of asthma or history of allergic rhinitis or atopy~* Patients treated with non-cardioselective β-blockers in the month preceding the screening visit~* Patients treated for exacerbations in the 4 weeks prior to screening visit~* Patients treated with long-acting antihistamines unless taken at stable regimen at least 2 months prior to screening and to be maintained constant during the study or if taken as PRN~* Patients requiring long term (at least 12 hours daily) oxygen therapy for chronic hypoxemia~* Known respiratory disorders other than COPD~* Patients who have clinically significant cardiovascular condition

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Beclometasone/Formoterol/Glycopyrrolate (Type: EXPERIMENTAL): CHF 5993 pMDI 100/6/12.5 mcg 2 inhalations bid
- Beclometasone/Formoterol (Type: ACTIVE_COMPARATOR): Foster® 100/6 mcg 2 inhalations bid

Based on this trial design, predict the completion outcome and termination type (if applicable).